BOUNDLESS BIO, INC. Deferred Costs, Current
BOUNDLESS BIO, INC. (BOLD) had Deferred Costs, Current of $5.28 million as of 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued
us-gaap:DeferredCostsCurrent · last filed 2024-05-13
- 2024-03-31: Deferred Costs, Current $5.28M.
| Period end | Deferred Costs, Current |
|---|---|
| 2024-03-31 | $5.28M 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |